Company intelligence / Profile preview

Melacure Therapeutics

Uppsala, Sweden

Ownership: Private
Development stage: Other

Overview

Melacure Therapeutics was a Swedish biotechnology company focused on the development of novel treatments for malignant melanoma. A spin-off from Uppsala University, the company centered its research on the melanin-concentrating hormone (MCH) system and its receptor, MCHR1. Their work identified MCHR1 as a potential therapeutic target due to its expression in melanoma cells and its role in stimulating tumor growth. Melacure aimed to develop MCHR1 antagonists to inhibit this proliferation, supported by investments from firms such as HealthCap. Although the company was a pioneer in this specific pathway, it is no longer active and its programs have ceased development.

Therapeutic areas: Oncology
Modalities: Small moleculePeptides
Industry: Biotech

Partnerships

Uppsala University

Beyond the preview

Go deeper on Melacure Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Melacure Therapeutics.

Explore the full profile